Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
It has been announced that following Bristol-Myers Squibb’s (BMS) successful acquisition of Amylin Pharmaceuticals, AstraZeneca (AZ) has made an initial payment of approximately US $3.2 billion ...
Bristol-Myers Squibb Co. has announced it will acquire Amylin Pharmaceuticals for approximately US $5.3 billion in cash. Following the completion of this acquisition, Bristol-Myers Squibb will ...
Instead, this investigational medicine mimics the activity of two hormones: amylin and calcitonin. The former helps regulate blood sugar levels and controls satiety. The latter regulates calcium ...
LEN+TAB+ZAB (LTZ) harbors the potential to be the first long-acting combination treatment regimen with twice-yearly dosing. At CROI 2025, the primary results of a Phase 2 study evaluating the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results